|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:fulvestrant
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L02BA03
|
|
gptkbp:CASNumber
|
gptkb:129453-61-8
|
|
gptkbp:chemicalFormula
|
C32H47F5O3S
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to fulvestrant
|
|
gptkbp:drugClass
|
selective estrogen receptor degrader
|
|
gptkbp:eliminatedIn
|
fecal
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
40 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Faslodex
|
|
gptkbp:indication
|
postmenopausal women
hormone receptor-positive metastatic breast cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:AstraZeneca
|
|
gptkbp:mechanismOfAction
|
estrogen receptor antagonist
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:patent
|
gptkb:AstraZeneca
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
nausea
fatigue
headache
injection site pain
hot flashes
|
|
gptkbp:tradeNameOf
|
gptkb:fulvestrant
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:fulvestrant
gptkb:AstraZeneca_US
|
|
gptkbp:bfsLayer
|
6
|